Sign in
Taking people in United StatesPhase 1

Tests CD22 CAR T cells after CD19 CAR T cells in young leukemia patients

Tests CD22 CAR T cells in young people with returned or resistant B-cell leukemia.

Key facts

Who runs it
Stanford University
Where
Palo Alto, United StatesSee the site
Trial code
Registry title
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
Status
Recruiting
Phase
Phase 1
People taking part
28 people, planned
Started
13 May 2024
Expected to end
Feb 2027
Type of study
Interventional
Treatments tested
  • CD22CART infusion
  • Tisagenlecleucel
Record updated
1 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young adults whose B-cell acute lymphoblastic leukemia has come back or did not respond to treatment. They would get commercial tisagenlecleucel CAR T cells, then CD22 CAR T cells.

Age
From 1 year up to 25 years and 364 days old at enrollment.
Sex
All sexes can join.
Disease stage
B cell acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, confirmed by tissue tests.
Earlier treatment
Must meet the wash-out period since prior therapies for commercial KYMRIAH (tisagenlecleucel). Must have recovered from acute side effects of prior therapy. Prior CAR therapy: at least 30 days before apheresis. Prior allogeneic stem cell transplant: at least 100 days ago, no graft-versus-host disease, and no immunosuppressive drugs for at least 30 days.
Biomarker or test result
CD19 and CD22 must be shown on the leukemia cells, at any level.

Main reasons for not taking part

  • HIV, hepatitis B or hepatitis C infection, or an uncontrolled illness with symptoms
  • Very high blast count (50,000 blasts/μL or more) or fast-progressing disease
  • Active central nervous system disorder, or a heart attack or other significant heart disease within 12 months
  • Primary immunodeficiency, or autoimmune disease needing immunosuppression in the last 2 years
  • Severe immediate allergic reaction to similar compounds used in the study

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Diagnosis of histologically confirmed relapsed/refractory (R/R) B cell acute lymphoblastic leukemia (ALL)
  • Must be eligible to receive commercial KYMRIAH® (tisagenlecleucel) according to FDA approved package insert (refractory disease or in second or later relapse)
  • CD19 and CD22 expression must be demonstrated on malignant cells by immunohistochemistry or flow cytometry. CD19 and CD22 expression at any level of expression will be acceptable, as that is the standard for commercial KYMRIAH® (tisagenlecleucel) and the optimal level of CD22 expression is not well defined
  • Age: ≥ 1 year of age and ≤ 25 years and 364 days of age at time of enrollment
  • Performance Status: Participants > 16 years of age: Karnofsky ≥ 50%; Participants ≤ 16 years of age: Lansky scale ≥ 50%
  • Normal Organ and Marrow Function; Absolute Neutrophil Count (ANC) ≥ 750/uL*; Platelet count ≥ 50,000/uL*; Absolute Lymphocyte Count ALC > 150/uL*; Adequate renal, hepatic, pulmonary and cardiac function defined as:; Baseline oxygen saturation > 92% on room air; Creatinine within ULN for age or Creatinine clearance (as estimated by Cockcroft Gault Equation) ≥ 60 mL/min; Total bilirubin ≤ 1.5 mg/dl, except in Participants with Gilbert's syndrome. [Elevations related to leukemia involvement of the liver will not disqualify a subject]; Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) ≤ 10 x ULN (except in Participants with liver involvement by leukemia); Cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an Echocardiogram; if these cytopenias are not judged by the investigator to be due to underlying disease (i.e. potentially reversible with anti-neoplastic therapy); A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is due to disease, based on the results of bone marrow studies
  • Participants with Central Nervous System (CNS) involvement or a history of CNS involvement are eligible only in the absence of neurologic symptoms that may mask or interfere with neurological assessment of toxicity
  • Participants who have undergone autologous SCT with disease progression or relapse following SCT are eligible. Participants with history of allogeneic SCT must be at least 100 days from SCT, have no evidence of Graft versus Host Disease (GvHD), and no longer taking immunosuppressive agents for at least 30 days prior to enrollment
  • Females of child bearing potential and males of child fathering potential must be willing to practice birth control during and for 4 months post chemotherapy or for as long as Chimeric Antigen Receptor (CAR) T cells are detectable in peripheral blood
  • Females of child bearing potential must have negative pregnancy test
  • Must meet wash out period since prior therapies according to commercial KYMRIAH® (tisagenlecleucel) SOPs
  • Must have recovered from acute side effects from prior therapy to meet eligibility
  • If had prior CAR therapy, will be eligible if at least 30 days has elapsed prior to apheresis
  • Ability to give informed consent. All Participants ≥ 18 years of age must be able to give informed consent. For participants <18 years old their legal authorized representative (LAR) (i.e. parent or guardian) must give informed consent. Pediatric participants will be included in age appropriate discussion and assent per institutional SOPs will be obtained for those > 7 years of age, when appropriate. If a minor becomes of age during participation of this study, he/she will be asked to reconsent as an adult; A subject will not be excluded because of pancytopenia ≥ Grade 3 if it is felt by the investigator to be due to underlying disease

Who cannot take part

  • May not have Human Immunodeficiency Virus (HIV)/Hepatitis B (HBV) or Hepatitis C (HCV infection) or uncontrolled, symptomatic, intercurrent illness
  • May not have hyperleukocytosis (≥ 50,000 blasts/μL) or rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy
  • May not have severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study
  • May not have active CNS disorder, or history of MI, cardiac angioplasty or stenting, unstable angina or other clinically significant cardiac disease with 12 months of enrollment
  • May not have primary immunodeficiency or history of autoimmune disease (e.g. Crohns, rheumatoid arthritis, systemic lupus) requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 25 years old?

Where in United States

  • Stanford UniversityPalo Alto, United StatesContact: Michelle FujimotoTaking people

About the trial

What the trial wants to find out

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cells when administered 28 to 42 days after an infusion of a commercial CAR called Tisagenlecleucel, to children and young adults with relapsed or refractory B-cell leukemia.

The group in the trial

  • LymphodepletionTreatment being tested

    All enrolled participants will receive lymphodepletion followed by standard of care tisagenlecleucel infusion.

    Treatment: CD22CART infusion and Tisagenlecleucel

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells Following Commercial CD19 CAR T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
Plain-language title
Tests CD22 CAR T cells after CD19 CAR T cells in young leukemia patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06408194, who can take part
Publications
Record updated
1 September 2026